Skip to content

Current ratio at other companies

Amgen logo
AmgenAMGN
1.3×+0.1×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
14.2×-4.3×
Nuvation Bio logo
Nuvation BioNUVB
7.4×-1.6×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.9×+1.9×
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
4.6×+1.0×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
1.2×-0.8×

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's current ratio?
Rigel Pharmaceuticals (RIGL) reported current ratio of 2.6× in Q1 2026.
How has Rigel Pharmaceuticals's current ratio changed year-over-year?
Rigel Pharmaceuticals's current ratio increased by 18.9% year-over-year, from 2.2× to 2.6×.
What is the long-term trend for Rigel Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's current ratio has grown at a 2.1% compound annual growth rate (CAGR), from 2.2× to 2.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.